Panitumumab is a fully humanized monoclonal Immunoglobulin G2 antibody that has a high-affinity binding to epidermal growth factor receptor (EGFR), a protein receptor overexpressed in many cancer types in dogs, cats and humans (2, 5, 9, 73–80). The gene discussed is EGFR; the disease is cancer.